glp 1 agonists vs sglt2 inhibitors Recommendations for SGLT2i versus GLP-1 RA on the basis of kidney GLP-1 receptor agonists vs. SGLT-2

Craig, C

Importantly, the triagonist also lowered fasting blood glucose levels and improved glucose tolerance without inducing hypoglycemia

Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials: efficacy endpoint for alcohol trials

These secondary targets are not interchangeable

Novos acquisition of Catalent facilities to meet growing demand reflects a strategic move to strengthen production capacity

The Trump administration announced initiatives in November 2025 to expand GLP-1 access for Medicare beneficiaries with obesity plus significant comorbidities, with implementation expected around mid-2026